Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis
- ExoCordOA, a five-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clinical development, regulation, GMP manufacturing, imaging, academia and healthcare
- Consortium will advance EXO-101 towards clinical validation as a potential disease-modifying treatment for osteoarthritis
- Programme also aims to address scientific, manufacturing, quality-control and regulatory barriers across the extracellular vesicle and secretome therapeutics field
Cantanhede, Portugal, 29 October – The ExoCordOA consortium today announced the launch of a five-year, €13 million project, funded by Horizon Europe to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis.
